Rocket Pharmaceuticals officer granted stock awards

Rocket Pharmaceuticals officer John Militello received new equity awards.

Rhea-AI Filing Summary

Rocket Pharmaceuticals officer John Militello received new equity awards. On February 11, 2026, he was granted 29,982 shares of common stock at a price of $0, increasing his directly held common stock to 95,902 shares.

He was also granted a stock option covering 45,018 shares at an exercise price of $3.24 per share. Both the restricted stock units and the option vest one-third on February 11, 2027, with the remaining portions vesting in equal quarterly installments over the following two years, subject to continued employment.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 2 txns

Insider Militello John

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	45,018	$0.00	$0.00
Grant/Award	Common Stock	29,982	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 45,018 contracts (Direct); Common Stock — 95,902 shares (Direct)

Footnotes (3)

1. F1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
2. F2. Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.
3. F3. This option represents a right to purchase a total of 45,018 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Rocket Pharmaceuticals (RCKT) report for John Militello?

Rocket Pharmaceuticals reported that officer John Militello received equity awards on February 11, 2026. He was granted 29,982 shares of common stock for $0 and a stock option for 45,018 shares with a $3.24 exercise price, all held directly.

How many Rocket Pharmaceuticals (RCKT) shares does John Militello hold after this Form 4?

After the reported grants, John Militello beneficially owns 95,902 shares of Rocket Pharmaceuticals common stock. This total includes restricted stock units that convert to common shares on a one-for-one basis, reflecting his direct equity stake following the February 11, 2026 awards.

What are the vesting terms of John Militello’s RSUs at Rocket Pharmaceuticals (RCKT)?

The 29,982 restricted stock units granted to John Militello vest over three years. One-third becomes fully vested on February 11, 2027, with the remaining RSUs vesting in equal quarterly installments during the following two years, contingent on his continued employment with Rocket Pharmaceuticals.

What are the key details of John Militello’s stock option grant at Rocket Pharmaceuticals (RCKT)?

John Militello received a stock option to purchase 45,018 Rocket Pharmaceuticals common shares at a $3.24 exercise price. One-third becomes vested and exercisable on February 11, 2027, with the balance vesting in equal quarterly installments over the next two years, subject to continued employment.

Does the Form 4 for Rocket Pharmaceuticals (RCKT) show a stock purchase or a grant for John Militello?

The Form 4 shows equity grants, not an open-market purchase. John Militello acquired 29,982 common shares and 45,018 stock options as awards priced at $0 for the grant itself, with the option exercisable later at a $3.24 per-share exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:05 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Militello John

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NJ 08512

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	02/11/2026		A		29,982(2)	A	$0	95,902(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.24	02/11/2026		A		45,018		(3)	02/11/2036	Common Stock	45,018	$0	45,018	D

Explanation of Responses:

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

2. Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.

3. This option represents a right to purchase a total of 45,018 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

	/s/ Martin Wilson, as attorney-in-fact for John Militello	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.